Axios had an item this morning on rising drug prices that, at first blush, doesn’t seem especially unusual. After all, the rising costs of medicines isn’t exactly new.
But there’s a political subtext to this that shouldn’t go unnoticed.
A handful of drug companies rang in 2018 with price hikes that easily surpass inflation but stay conspicuously below double digits, my colleague Bob Herman reports. Investment banks Jefferies and Cowen highlighted some of the big ones:
AbbVie’s blockbuster Humira: 9.7%Amgen’s arthritis medicine Enbrel: 9.7%Allergan’s dry eye drug Restasis: 9.5%Insys Therapeutics’ opioid spray Subsys: 9.5%Biogen’s multiple sclerosis drug Tecfidera: 8%
The piece added that prices are expected to continue to rise, and according to the investment banks’ analyses, there’s “almost no chance U.S. drug price controls will occur in the next three years.”
Again, none of this is especially surprising. What is surprising is the fact that the political world has largely forgotten about Donald Trump’s promise to tackle this issue head on — a vow that quietly fell down the memory hole.
As regular readers may recall, one of the few key areas on which Donald Trump broke with Republican Party orthodoxy was lowering prices on prescription drugs. In fact, shortly before taking office, he complained bitterly about the pharmaceutical industry’s powerful lobbyists, and said drug companies are “getting away with murder.”









